BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the U.S. and European women's health imaging system market will remain stable through 2022. This will be largely due to emerging breast imaging system segments growing quickly, balancing declines in the more mature markets. By 2022, the combined U.S. and European market—including France, Germany, Italy, Spain and the United Kingdom—will be valued at approximately $1.3 billion.

Other key findings from Decision Resources Group's coverage of the U.S. and European women's health imaging system markets:

  • Rapid adoption of new breast imaging modalities: Newer modalities for breast imaging, such as breast tomosynthesis and breast-specific gamma imaging, have generated significant interest in the U.S. and Europe. These technologies can offer higher-quality imaging than traditional mammography systems and therefore represent powerful options for secondary screening, especially for women with dense breasts.
  • Adoption in Europe versus the U.S.: Adoption of these newer breast imaging systems will be faster in Europe compared to the U.S. This is largely because the European market features several large and established competitors that have been promoting these products. By contrast, only a handful of companies have approval to sell these products in the U.S. For example, Hologic was the only competitor offering a breast tomosynthesis system in the U.S. in 2013, partially as a result of the requirement for companies to go through the lengthy premarket approval process.
  • Flat markets for OB/GYN ultrasound and bone densitometry systems: Despite innovation in system functionality and visualization quality, the OB/GYN ultrasound system market will experience flat growth in both Europe and the U.S. as a result of high installed base volumes with little room for expansion to new facilities. Similarly, the bone densitometry market is highly saturated, with central dual energy X-ray absorptiometry systems remaining the gold standard product in the industry for both regions. 

Comments from Decision Resources Group Analyst Clare Gora:

  • "Both the U.S. and European markets are dominated by large companies with broad product lines, such as GE Healthcare, Siemens Healthcare, Philips Healthcare and Hologic. However, these companies have been gradually losing share to newer companies, such as Samsung and Mindray Medical International, which offer lower-cost systems."

Comments from Decision Resources Group Analyst Stephanie Wood:

  • "The ongoing economic concerns in Europe will continue to affect the women's health imaging system market—this will be most notable in the Italian and Spanish markets, which will decline strongly at the beginning of the forecast period."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Asia Pacific Spinal Implant and Bone Graft Substitute Market Will More than Double to Nearly $7 Billion by 2022

View Now